Form 4 for AMGN Amgen
Accepted 2023-03-08 00:00:00 ET · period of report 2023-03-06 · accession 0001127602-23-009503 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-03-08 | 2023-03-06 | AMGN | Graham Jonathan P | EVP, Gen. Counsel, Secy | A - Grant | $0.00 | +7,560 | 41.6K | +22% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-06 | A | A | 7,560 | $0.00 | 41,620 | D | — | — | (F2) These shares include 922 DEs granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. (F1) These shares include the following RSUs granted under the Company's equity plans: 1,074 RSUs which will vest on 5/3/2023; 3,120 RSUs which will vest on 11/1/2023; 2,211 RSUs which will vest in installments of 1,089 on 5/5/2023 and 1,122 on 5/5/2024; 3,797 RSUs which will vest in two installments of 1,253 on 4/30/2023 and 4/30/2024 and one installment of 1,291 on 4/30/2025; and 3,377 RSUs which will vest in two installments of 1,114 on 5/2/2024 and 5/2/2025, and one installment of 1,149 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. |